SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001094038

MRKR

Marker Therapeutics, Inc.
$1.05 ▲ +0.00%
Prev close $1.05
Market cap$17.8M
12-mo target$7.87 (+649.2%)
Biotech & Drug Discovery
Snapshot
The big-picture read on MRKR right now — valuation, ownership and activity at a glance.
Market Cap
$17.8M
Cap Size
Nano Cap
Inst. Holders
22 funds
Inst. Value
$2.0M
Inst. Activity
2 buys / 2 sells
SEC Reports
2
Press Releases
1
Price chart 30d -16.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 12, 2026 earnings_calendar
MRKR Q2 2026 Earnings Scheduled — 2026-08-12
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
249,423 shares ($366.7K)
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — ADD
34,629 shares ($50.9K)
Mar 20, 2026 SEC
Marker Therapeutics is holding its 2026 annual meeting where shareholders will vote on several proposals, including the
DEFA14A — Impact 4/10
Mar 19, 2026 SEC
Marker Therapeutics reported its 2025 financial results and provided clinical updates, highlighting a 66% objective resp
8-K — Impact 6/10
Mar 18, 2026 Press
Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower
Impact 6/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
DateFirmActionRatingFirm rating
Dec 8, 2025HC Wainwright & Co.INITIATEBuy 43%
Apr 1, 2025WBB SecuritiesREITERATEStrong Buy—
Mar 5, 2025Canaccord GenuityINITIATEBuy 47%
Apr 30, 2024Ladenburg ThalmannINITIATEBuy 45%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 20262610089%
Aug 1, 20262610089%
Jul 1, 20262610089%
Jun 1, 20262610089%
May 1, 20262610089%
Apr 1, 20262610089%
Mar 1, 20262610089%
Feb 1, 20262610089%
Price targets
Where 3 covering analysts think MRKR trades over the next 12 months.
$7.87 +649.2% upside Strong Buy
Current$1.05 Low$5.60 Median$8.00 High$10.00 3 analysts
$5.60$10.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
2 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 1 neutral · avg impact 5.0/10.Plus 1 press releases.
NEUTRALDEFA14A4/10
Marker Therapeutics is holding its 2026 annual meeting where shareholders will vote on several propo
Mar 20, 2026
MIXED8-K6/10
Marker Therapeutics reported its 2025 financial results and provided clinical updates, highlighting
Mar 19, 2026
MIXED6/10
Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 m
Mar 18, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 12, 2026
earnings_calendar
MRKR Q2 2026 Earnings Scheduled — 2026-08-12
May 13, 2026
earnings_calendar
MRKR Q1 2026 Earnings Scheduled — 2026-05-13
Mar 30, 2026
earnings_calendar
MRKR Q4 2025 Earnings After Market Close — 2026-03-30
Mar 18, 2026
earnings
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.14$-0.16–$-0.12-16.7%+24.3%1↑ 0↓$0.0B2
Next Q$-0.17$-0.22–$-0.12-325.0%+0.0%—$0.0B2
Current FY$-0.56$-0.63–$-0.5026.1%+18.1%2↑ 0↓$0.0B2
Next FY$-0.53$-0.89–$-0.176.2%+29.8%1↑ 0↓$0.0B2
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.140—
7d ago$-0.185+0.045
30d ago$-0.185+0.045
60d ago$-0.120-0.020
90d ago$-0.120-0.020
Institutional ownership
Which big funds own MRKR (from quarterly 13F filings) and who is adding or trimming.
22 institutional holders with $2.0M total value (1,370,058 shares) as of 2026-Q2. Top holders: VANGUARD, RENAISSANCE, GEODE.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
VANGUARD CAPITAL MANAGEMENT LLC426,169$626.5K31.1%—
RENAISSANCE TECHNOLOGIES LLC249,423$366.7K18.2%ADD +42.3%
GEODE CAPITAL MANAGEMENT, LLC139,816$205.6K10.2%ADD +35.3%
OSAIC HOLDINGS, INC.112,649$165.6K8.2%DOUBLED +552.5%
VANGUARD FIDUCIARY TRUST CO87,269$128.3K6.4%—
LPL Financial LLC83,147$122.2K6.1%ADD +41.7%
Concurrent Investment Advisors, LLC67,963$99.9K5.0%—
TWO SIGMA INVESTMENTS, LP60,201$88.5K4.4%DOUBLED +168.6%
NORTHERN TRUST CORP34,629$50.9K2.5%ADD +33.1%
CITADEL ADVISORS LLC32,517$47.8K2.4%—
Recent position changes
FundActionPrevCurrentChangeValue
RENAISSANCE TECHNOLOGIES LLCADD175,294249,423+42.3%$366.7K
NORTHERN TRUST CORPADD26,00934,629+33.1%$50.9K
JANE STREET GROUP, LLCTRIM36,30316,832-53.6%$24.7K
UBS Group AGTRIM32,3698,150-74.8%$12.0K
RENAISSANCE TECHNOLOGIES LLCADD123,650175,294+41.8%$227.9K
UBS Group AGNEAR_EXIT174,02632,369-81.4%$42.1K
MORGAN STANLEYNEAR_EXIT152-86.7%$2.00
UBS Group AGDOUBLED5,794174,026+2903.6%$259.3K
GEODE CAPITAL MANAGEMENT, LLCADD96,316130,344+35.3%$194.2K
TWO SIGMA INVESTMENTS, LPDOUBLED36,54098,141+168.6%$146.2K
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MRKR.
Shares short
226,620
Settlement Sep 15, 2026
Change vs prior
+62.8%
Semi-monthly cycle
Days to cover
3.3
At avg daily volume
Of shares outstanding
≈1.4%
Estimate — not % of float
All MRKR filing & press-release reports (3)